Viral variants that initiate and drive maturation of V1V2-directed HIV-1 broadly neutralizing antibodies

The elicitation of broadly neutralizing antibodies (bNAbs) is likely to be essential for a preventative HIV-1 vaccine, but this has not yet been achieved by immunization. In contrast, some HIV-1-infected individuals naturally mount bNAb responses during chronic infection, suggesting that years of maturation may be required for neutralization breadth. Recent studies have shown that viral diversification precedes the emergence of bNAbs, but the significance of this observation is unknown. Here we delineate the key viral events that drove neutralization breadth within the CAP256-VRC26 family of 33 monoclonal antibodies (mAbs) isolated from a superinfected individual. First, we identified minority viral variants, termed bNAb-initiating envelopes, that were distinct from both of the transmitted/founder (T/F) viruses and that efficiently engaged the bNAb precursor. Second, deep sequencing revealed a pool of diverse epitope variants (immunotypes) that were preferentially neutralized by broader members of the antibody lineage. In contrast, a 'dead-end' antibody sublineage unable to neutralize these immunotypes showed limited evolution and failed to develop breadth. Thus, early viral escape at key antibody-virus contact sites selects for antibody sublineages that can tolerate these changes, thereby providing a mechanism for the generation of neutralization breadth within a developing antibody lineage.

[1]  Chaim A. Schramm,et al.  Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies , 2014, Nature.

[2]  Richard T. Wyatt,et al.  Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals , 2009, Nature.

[3]  A. Brink The South African Medical Research Council , 1973 .

[4]  J. Sodroski,et al.  Molecular cloning and analysis of functional envelope genes from human immunodeficiency virus type 1 sequence subtypes A through G. The WHO and NIAID Networks for HIV Isolation and Characterization , 1996, Journal of virology.

[5]  Florian Klein,et al.  Antibodies in HIV-1 Vaccine Development and Therapy , 2013, Science.

[6]  L. Morris,et al.  Viral Escape from HIV-1 Neutralizing Antibodies Drives Increased Plasma Neutralization Breadth through Sequential Recognition of Multiple Epitopes and Immunotypes , 2013, PLoS pathogens.

[7]  Daniel J. Blankenberg,et al.  Galaxy: A Web‐Based Genome Analysis Tool for Experimentalists , 2010, Current protocols in molecular biology.

[8]  B. Korber,et al.  Prevalence of broadly neutralizing antibody responses during chronic HIV-1 infection , 2014, AIDS.

[9]  C. Gray,et al.  Establishing a Cohort at High Risk of HIV Infection in South Africa: Challenges and Experiences of the CAPRISA 002 Acute Infection Study , 2008, PloS one.

[10]  Feng Gao,et al.  Cooperation of B Cell Lineages in Induction of HIV-1-Broadly Neutralizing Antibodies , 2014, Cell.

[11]  M. Nussenzweig,et al.  Predominant Autoantibody Production by Early Human B Cell Precursors , 2003, Science.

[12]  Pham Phung,et al.  Broad and Potent Neutralizing Antibodies from an African Donor Reveal a New HIV-1 Vaccine Target , 2009, Science.

[13]  John D. Hunter,et al.  Matplotlib: A 2D Graphics Environment , 2007, Computing in Science & Engineering.

[14]  K. Katoh,et al.  MAFFT Multiple Sequence Alignment Software Version 7: Improvements in Performance and Usability , 2013, Molecular biology and evolution.

[15]  Lynn Morris,et al.  Evolution of an HIV glycan–dependent broadly neutralizing antibody epitope through immune escape , 2012, Nature Medicine.

[16]  S. Segawa,et al.  End of the beginning , 1990, Nature.

[17]  T. A. Hall,et al.  BIOEDIT: A USER-FRIENDLY BIOLOGICAL SEQUENCE ALIGNMENT EDITOR AND ANALYSIS PROGRAM FOR WINDOWS 95/98/ NT , 1999 .

[18]  James E. Crowe,et al.  Human Peripheral Blood Antibodies with Long HCDR3s Are Established Primarily at Original Recombination Using a Limited Subset of Germline Genes , 2012, PloS one.

[19]  A. Nekrutenko,et al.  Galaxy: a comprehensive approach for supporting accessible, reproducible, and transparent computational research in the life sciences , 2010, Genome Biology.

[20]  Martin A. Nowak,et al.  Antibody neutralization and escape by HIV-1 , 2003, Nature.

[21]  L. Morris,et al.  Multiple Pathways of Escape from HIV Broadly Cross-Neutralizing V2-Dependent Antibodies , 2013, Journal of Virology.

[22]  Cassandra B. Jabara,et al.  Accurate sampling and deep sequencing of the HIV-1 protease gene using a Primer ID , 2011, Proceedings of the National Academy of Sciences.

[23]  David Nemazee,et al.  Rational immunogen design to target specific germline B cell receptors , 2012, Retrovirology.

[24]  Robert C. Edgar,et al.  MUSCLE: multiple sequence alignment with high accuracy and high throughput. , 2004, Nucleic acids research.

[25]  Anton Nekrutenko,et al.  Manipulation of FASTQ data with Galaxy , 2010, Bioinform..

[26]  W. Delano The PyMOL Molecular Graphics System , 2002 .

[27]  Lynn Morris,et al.  New Member of the V1V2-Directed CAP256-VRC26 Lineage That Shows Increased Breadth and Exceptional Potency , 2015, Journal of Virology.

[28]  Pham Phung,et al.  Broad neutralization coverage of HIV by multiple highly potent antibodies , 2011, Nature.

[29]  G. Shaw,et al.  A rev1-vpu polymorphism unique to HIV-1 subtype A and C strains impairs envelope glycoprotein expression from rev-vpu-env cassettes and reduces virion infectivity in pseudotyping assays. , 2010, Virology.

[30]  J. Mascola,et al.  Broadly neutralizing antibodies and the search for an HIV-1 vaccine: the end of the beginning , 2013, Nature Reviews Immunology.

[31]  K. Katoh,et al.  Improvements in Performance and Usability , 2013 .

[32]  Daniel J. Blankenberg,et al.  Galaxy: a platform for interactive large-scale genome analysis. , 2005, Genome research.

[33]  J. Baeten,et al.  Breadth of Neutralizing Antibody Response to Human Immunodeficiency Virus Type 1 Is Affected by Factors Early in Infection but Does Not Influence Disease Progression , 2009, Journal of Virology.

[34]  Dennis R. Burton,et al.  A Limited Number of Antibody Specificities Mediate Broad and Potent Serum Neutralization in Selected HIV-1 Infected Individuals , 2010, PLoS pathogens.

[35]  John P. Moore,et al.  Recombinant HIV envelope trimer selects for quaternary-dependent antibodies targeting the trimer apex , 2014, Proceedings of the National Academy of Sciences.

[36]  S. Travers,et al.  RAMICS: trainable, high-speed and biologically relevant alignment of high-throughput sequencing reads to coding DNA , 2014, Nucleic acids research.

[37]  L. Morris,et al.  The Neutralization Breadth of HIV-1 Develops Incrementally over Four Years and Is Associated with CD4+ T Cell Decline and High Viral Load during Acute Infection , 2011, Journal of Virology.

[38]  H. Schuitemaker,et al.  Longitudinal Analysis of Early HIV-1-Specific Neutralizing Activity in an Elite Neutralizer and in Five Patients Who Developed Cross-Reactive Neutralizing Activity , 2011, Journal of Virology.

[39]  B. Korber,et al.  Deciphering Human Immunodeficiency Virus Type 1 Transmission and Early Envelope Diversification by Single-Genome Amplification and Sequencing , 2008, Journal of Virology.

[40]  Qing Zhu,et al.  Rapid development of broadly influenza neutralizing antibodies through redundant mutations , 2014, Nature.

[41]  Xuesong Yu,et al.  Factors Associated with the Development of Cross-Reactive Neutralizing Antibodies during Human Immunodeficiency Virus Type 1 Infection , 2008, Journal of Virology.

[42]  M. Nussenzweig,et al.  Memory B Cell Antibodies to HIV-1 gp140 Cloned from Individuals Infected with Clade A and B Viruses , 2011, PloS one.

[43]  B. Haynes,et al.  HIV‐1 neutralizing antibodies: understanding nature's pathways , 2013, Immunological reviews.

[44]  Chaim A. Schramm,et al.  Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus , 2013, Nature.

[45]  L. Stamatatos,et al.  Engineering HIV envelope protein to activate germline B cell receptors of broadly neutralizing anti-CD4 binding site antibodies , 2013, The Journal of experimental medicine.